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repression of NFAT and AP-1 that has
been reported in Tim-2 transfectants
(Knickelbein et al., 2006). The exis-
tence of multiple binding modes could
translate into triggering of multiple
biochemical signaling modes and
different functional outcomes depend-
ing on which ligand(s) are binding to
the Tims. Lastly, whether signaling
pathways will synergize or antagonize
if two ligands bind to two different
faces of the Tim molecules remains
to be seen.
Thus, the accumulating biological
data that underscore the importance
of the Tim molecules in immunity
together with the structural data dis-
cussed above highlight the need for
understanding the complex interaction
of Tim molecules with their ligands.
How can this all take place? One can
envision that the regulation of complex
ligand:receptor interactions could take
place at different levels such as the an-
atomic distribution of different ligands,
differential affinity for different ligands,
and the modulation of the expression
of the Tims and different Tim ligands
by environmental triggers such as in-
flammation. The identification of novel
Tim ligands, their expression pattern
and measurements of the affinity of
different Tim:ligand pairs, and the elu-
cidation of the pattern and regulation
of Tim and Tim ligand expression will
likely fuel investigation in this field for
many years to come.
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Ikaros family members play an important role in hematopoietic development. Thompson et al. (2007)
show that pre-BCR signaling induces Aiolos expression, which in turn suppresses the expression of
the pre-BCR component l5 and eliminates the very structure that signaled its appearance.Ikaros burst into the scene of immune
gene regulation in the early nineties
(Georgopoulos et al., 1992; Lo et al.,
1991), leading to a flurry of research
that has generated a lot of data, not
always concordant. This seems likely
to be due to the multifarious potential
activities of this factor. Ikzf1, the gene
encoding Ikaros, is the prototype
member of a family of five known
(so far) genes, three of which have a
hematopoietic pattern of expression.Mutations in these genes usually result
in severe hemato-lymphopoietic disor-
ders (Ng et al., 2007; Papathanasiou
et al., 2003). Attempts to specify the
mode of action of the Ikaros-family
genes have not been straightforward.
Thus, some studies have shown Ikaros
to activate target genes (Harker et al.,
2002), whereas others showed that it
represses gene expression (Sabbattini
et al., 2001). The latter notion was sup-
ported by findings showing that IkarosImmunityis localized at pericentric heterochro-
matin, suggesting that genes bound
by Ikaros can be silenced by being
dragged into transcriptionally nonac-
tive compartments of the nucleus
(Brown et al., 1997; Hahm et al., 1998).
In this issue of Immunity, Thompson
et al. (2007) add another new and inter-
esting facet on the profile of this family
of factors. In early B cell development,
cells at the pre-BI stage express Igll1,
the gene encoding l5, a component26, March 2007 ª2007 Elsevier Inc. 275
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Previewsof the pre-B cell receptor complex
(pre-BCR). In the subsequent pre-BII
stage, cells downregulate pre-BCR
expression and acquire the immuno-
globulin BCR. Thompson et al. (2007)
here show that the balance between
Ikaros (which was shown to suppress
Igll1 expression) and the EBF tran-
scription factor (which activates Igll1
expression) determines l5 protein ex-
pression at the pre-BI stage. Such
competition between Ikaros and EBF
was predicted by earlier studies (Sab-
battini et al., 2001) and is confirmed
experimentally in the present paper.
One can imagine that the Ikaros:
EBF ratio would regulate l5 protein
expression also at the subsequent
pre-BII stage of B cell development,
and therefore an increase in Ikaros
protein expression would suffice to ef-
fect the observed suppression of Igll1
expression. However, the amounts of
Ikaros and EBF remain the same dur-
ing the transition from the pre-BI to
pre-BII stage, although we must bear
in mind that the total amount of protein
present does not always equal the
amount that is functionally active. Sur-
prisingly, it appears that another mem-
ber of the family steps in to carry out
the final inactivation of Igll1 expression
in mature B cells. Aiolos expression
increases dramatically at the pre-BII
stage, and this coincides with the
complete extinction of l5 protein ex-
pression. Interestingly, in the absence
of Aiolos, l5 protein is not completely
eliminated; this demonstrates that Aio-
los is required for the final cessation of
Igll1 gene expression.
In both pre-BI and pre-BII stages of
B cell development, the two Ikaros
members appear to be taking part in
a tug-of-war with other regulatory
factors, and the outcome of this war
depends on the amounts of each of
the players. A hypothesis put forward
a fewyears agoproposed that a gene’s
chromatin structure, and therefore its
potential to be expressed, is under
the control of mass action law (Kious-
sis and Festenstein, 1997). In other
words, an increase in the concentra-
tion of a repressive factor that induces
a closed (inactive) chromatin configu-
ration results in the silencing of the
gene under its control; conversely, an
increase of an activating factor will276 Immunity 26, March 2007 ª2007 Elslead to induction of transcription of a
target gene. The results in this paper
support this hypothesis. For instance,
increasing EBF in vitro seems to re-
verse the repressive effects of Ikaros
on expression of the Igll1 gene at the
pre-BI stage. Furthermore, later at
the pre-BII stage, the sudden increase
in Aiolos concentration manages to
overturn this action, and Igll1 gene ex-
pression is extinguished completely. It
will be very interesting to find corre-
lates of this type of regulation in other
types of cells. In that respect, it is inter-
esting that Aiolos expression goes up
also at the double-positive (DP) stage
during thymocyte development. How-
ever, Ikaros family members have
been associated with activation of a
target gene (Cd8a) in DP thymocytes
(Harker et al., 2002). Future studies
may show that other target genes in
thymocytes might respond differently
from Cd8a and more similarly to Igll1
in pre-B cells.
Finally, the paper shows that the in-
crease of Aiolos expression at the pre-
BII stage appears to be dependent on
signals initiated by the pre-BCR and
transmitted via SLP-65 and, possibly,
IRF-4. It would be interesting to find
out how and why high expression of
Aiolos is maintained even after its in-
ductive signals (originating from the
pre-BCR) have lapsed. Perhaps ma-
ture BCR replaces pre-BCR in this
function. An additional interesting
point is that in Aiolos-deficient mice,
the initial major reduction of Igll1
mRNA still takes place, and such a
finding indicates that additional mech-
anisms exist that contribute to the
downregulation of Igll1 expression. It
is as if Aiolos is needed to put the final
nail in the Igll1 transcription coffin. Al-
together, the data support a model in
which pre-BCR signals determine the
abolition of its own expression by a
feedback loop, which is regulated by at
least one of the members of the Ikaros
family of transcription factors, namely
Aiolos. Again, finding what induces
Aiolos expression in other cells, such
as the DP thymocytes, and whether a
feed back loop also operates in these
cells would add to our understanding
of the function of these factors.
This latter question of how the
Ikaros-family factors exert their effectevier Inc.on target genes still remains a puzzle.
How is it possible that the same factor
can activate some genes but suppress
others, and even more intriguing, how
can it activate one gene in one type
of cells and suppress the same gene
in another? Perhaps the answer lies
in the nature of the protein itself. Ikaros
family members have a modular com-
position with many domains of distinct
functions. One of the domains binds
DNA in a sequence-specific manner,
and this allows Ikaros to be recruited
onto genes carrying consensus Ikaros-
binding sequences. Indeed, chroma-
tin-immunoprecipitation studies have
shown that Ikaros is found to be a com-
ponent of the chromatin of such genes.
In these cases where Ikaros binds di-
rectly on the DNA of the target locus,
the positive or negative influence of
Ikaros on transcription is thought to be
due to additional transactivating and
repressing domains within the protein
itself (Figure 1A).
In addition to the domain that binds
DNA directly, these factors also have
domains that allow protein-protein in-
teractions, and this introduces an ad-
ditional layer of complexity. Thus, their
ability to associate with other tran-
sactivating or repressing transcription
factors and chromatin-remodeling
machineries could also determine the
final outcome. Thus, after direct DNA
Ikaros binding, recruitment of a sup-
pressive chromatin remodeler could
close down local chromatin, and this
could lead to the silencing of the
gene; conversely, recruitment of an
activating machinery would lead to
induction of expression (Figure 1B).
However, under certain circum-
stances, Ikaros family members have
the additional ability to cause reposi-
tioning of a gene to inactive hetero-
chromatic regions in the nucleus.
Such an action is thought to lead to
suppression of expression.
What determines then which of the
activities described above will take
place when Ikaros and company asso-
ciate with a gene? Perhaps Ikaros is
recruited into the chromatin structure
of a gene not as a result of direct
DNA binding but indirectly via protein-
protein interactions with complexes,
which are already present on the
gene under consideration (Figure 1C).
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PreviewsFigure 1. Ikaros Family Members May Employ One of Several Mechanisms in order
to Regulate Target Gene Expression
After direct binding onto theDNAof the target gene, Ikaros canactivate ([A], left) or silence ([A], right)
this gene’s transcription by using its own transactivation or suppression domains. Alternatively,
Ikaros can achieve similar results by recruiting remodeling complexes onto the target’s gene chro-
matin and thus activate ([B], left) or suppress ([B], right) domains. After interactions with complexes
that are already present on target genes’ chromatin (indirect binding), Ikaros could also potentially
drag a locus into transcriptionally inactive areas of the nucleus to silence the gene (C).It is possible that silencing of a gene
after its repositioning into heterochro-
matic compartments of the nucleus is
achieved subsequently to an indirect
mode of Ikaros binding. In contrast, di-
rect DNA binding would lead to gene
activation or suppression because of
either inherent activating or suppress-
ing activities of Ikaros domains or
because of differential recruitment of
different chromatin remodelers on thetarget gene, without the need to recruit
the locus to heterochromatic nuclear
compartments (Sabbattini et al.,
2001).
In conclusion, the work described
by Thompson et al. (2007) confirms
that the balance of opposing activities
of Ikaros and other activating tran-
scription factors determine the tran-
scriptional activity of a target locus
and adds another step in the regula-Immunitytion of target genes by Ikaros family
members by showing that Aiolos is re-
sponsible for shutting down the very
gene that induced its own expression
in the first place.
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